Currently out of the existing stock ratings of Keay Nakae, 234 are a BUY (87.97%), 24 are a HOLD (9.02%), 8 are a SELL (3.01%).

Keay Nakae

Work Performance Price Targets & Ratings Chart

Analyst Keay Nakae, currently employed at CHARDAN CAPITAL, carries an average stock price target met ratio of 40.29% that have a potential upside of 38.02% achieved within 106 days.

Keay Nakae’s has documented 468 price targets and ratings displayed on 39 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on IBIO, Ibio at 18-Mar-2026.

Wall Street Analyst Keay Nakae

Analyst best performing recommendations are on KMDA (KAMADA).
The best stock recommendation documented was for EVLO (EVELO BIOSCIENCES) at 11/1/2021. The price target of $240 was fulfilled within 4 days with a profit of $50.6 (26.72%) receiving and performance score of 66.79.

Average potential price target upside

of $53.2 (28.51%) on EVLO (EVELO BIOSCIENCES).
of $49 (27.5%) on ALNY (ALNYLAM PHARMACEUTICALS).
of $27.58 (110.89%) on ARWR (ARROWHEAD PHARMACEUTICALS).

ABUS Arbutus Biopharma Corp ARWR Arrowhead Pharmaceuticals AXLA Axcella Health DRNA Dicerna Pharmaceuticals EBS Emergent Biosolutions KLDO Kaleido Biosciences MESO Mesoblast Ltd OCGN Ocugen PEAR Pear Therapeutics SONN Sonnet Biotherapeutics Holdings EVLO Evelo Biosciences FBRX Forte Biosciences LJPC La Jolla Pharmaceutical Co PHGE Biomx PRQR ProQR Therapeutics BV CFRX ContraFect Corp FEMY Femasys NBSE NeuBase Therapeutics RNA Avidity Biosciences SABS SAB Biotherapeutics MCRB Seres Therapeutics SYBX Synlogic ALNY Alnylam Pharmaceuticals BTTX Better Therapeutics DYN Dyne Therapeutics GANX Gain Therapeutics KMDA Kamada OCX OncoCyte Corp SLN Silence Therapeutics PLC XCUR Exicure OMGA Omega Therapeutics IBIO Ibio ALUR Allurion Technologies COYA Coya Therapeutics, Common Stock NTBL Notable Labs OBIO Orchestra BioMed Holdings CLBS Caladrius Biosciences MBOT Microbot Medical MNPR Monopar Therapeutics

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Keay Nakae (CHARDAN CAPITAL)